Sökning: WFRF:(Kontny Frederic) > Rationale, design a...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 08828naa a2201501 4500 | |
001 | oai:DiVA.org:uu-387294 | |
003 | SwePub | |
008 | 190624s2019 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3872942 URI |
024 | 7 | a https://doi.org/10.1002/clc.231642 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Bhatt, Deepak L.u Harvard Med Sch, Brigham & Womens Hosp, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA4 aut |
245 | 1 0 | a Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study |
264 | c 2019-04-09 | |
264 | 1 | b Wiley,c 2019 |
338 | a electronic2 rdacarrier | |
520 | a In the setting of prior myocardial infarction, the oral antiplatelet ticagrelor added to aspirin reduced the risk of recurrent ischemic events, especially, in those with diabetes mellitus. Patients with stable coronary disease and diabetes are also at elevated risk and might benefit from dual antiplatelet therapy. The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS, NCT01991795) is a Phase 3b randomized, double-blinded, placebo-controlled trial of ticagrelor vs placebo, on top of low dose aspirin. Patients >= 50 years with type 2 diabetes receiving anti-diabetic medications for at least 6 months with stable coronary artery disease as determined by a history of previous percutaneous coronary intervention, bypass grafting, or angiographic stenosis of >= 50% of at least one coronary artery were enrolled. Patients with known prior myocardial infarction (MI) or stroke were excluded. The primary efficacy endpoint is a composite of cardiovascular death, myocardial infarction, or stroke. The primary safety endpoint is Thrombolysis in Myocardial Infarction major bleeding. A total of 19 220 patients worldwide have been randomized and at least 1385 adjudicated primary efficacy endpoint events are expected to be available for analysis, with an expected average follow-up of 40 months (maximum 58 months). Most of the exposure is on a 60 mg twice daily dose, as the dose was lowered from 90 mg twice daily partway into the study. The results may revise the boundaries of efficacy for dual antiplatelet therapy and whether it has a role outside acute coronary syndromes, prior myocardial infarction, or percutaneous coronary intervention. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng |
653 | a antiplatelet therapy | |
653 | a clinical trials | |
653 | a diabetes mellitus | |
653 | a general clinical cardiology | |
653 | a adult | |
653 | a ischemic heart disease | |
700 | 1 | a Fox, Kimu Imperial Coll, Natl Heart & Lung Inst, London, England;Royal Brompton Hosp, London, England4 aut |
700 | 1 | a Harrington, Robert A.u Stanford Univ, Dept Med, SCCR, Stanford, CA 94305 USA4 aut |
700 | 1 | a Leiter, Lawrence A.u Univ Toronto, St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada4 aut |
700 | 1 | a Mehta, Shamir R.u Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON, Canada;McMaster Univ, Hamilton, ON, Canada4 aut |
700 | 1 | a Simon, Tabassomeu Sorbonne Univ Paris, Hop St Antoine, AP HP, Dept Clin Pharmacol URCEST, Paris, France4 aut |
700 | 1 | a Andersson, Marielleu AstraZeneca Gothenburg, Dept Cardiovasc Renal & Metab, Molndal, Sweden4 aut |
700 | 1 | a Himmelmann, Andersu AstraZeneca Gothenburg, Dept Cardiovasc Renal & Metab, Molndal, Sweden4 aut |
700 | 1 | a Ridderstrale, Wilhelmu AstraZeneca Gothenburg, Dept Cardiovasc Renal & Metab, Molndal, Sweden4 aut |
700 | 1 | a Held, Claes,d 1956-u Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi,Uppsala Univ, Uppsala Clin Res Ctr, Dept Med Sci, Cardiol, Uppsala, Sweden4 aut0 (Swepub:uu)clahe947 |
700 | 1 | a Steg, Philippe Gabrielu Univ Paris Diderot, Hop Bichat, AP HP, Dept Hosp Univ FIRE,F CRIN Network,FACT, Paris, France;Univ Paris Diderot, Hop Bichat, AP HP, Dept Hosp Univ FIRE,INSERM,U 1148, Paris, France;Imperial Coll, Royal Brompton Hosp, NHLI, London, England4 aut |
700 | 1 | a Steg, Gabriel4 aut |
700 | 1 | a Diaz, Rafael4 aut |
700 | 1 | a Amerena, John4 aut |
700 | 1 | a Huber, Kurt4 aut |
700 | 1 | a Sinnaeve, Peter4 aut |
700 | 1 | a Nicolau, Jose Carlos4 aut |
700 | 1 | a Kerr Saraiva, Jose Francisco4 aut |
700 | 1 | a Petrov, Ivo4 aut |
700 | 1 | a Corbalan, Ramon4 aut |
700 | 1 | a Ge, Junbo4 aut |
700 | 1 | a Zhao, Qiang4 aut |
700 | 1 | a Botero, Rodrigo4 aut |
700 | 1 | a Widimsky, Petr4 aut |
700 | 1 | a Kristensen, Steen Dalby4 aut |
700 | 1 | a Hartikainen, Juha4 aut |
700 | 1 | a Danchin, Nicolas4 aut |
700 | 1 | a Darius, Harald4 aut |
700 | 1 | a Fat, Tse Hung4 aut |
700 | 1 | a Kiss, Robert Gabor4 aut |
700 | 1 | a Pais, Prem4 aut |
700 | 1 | a Lev, Eli4 aut |
700 | 1 | a De Luca, Leonardo4 aut |
700 | 1 | a Goto, Shinya4 aut |
700 | 1 | a Ramos Lopez, Gabriel Arturo4 aut |
700 | 1 | a Cornel, Jan Hein4 aut |
700 | 1 | a Kontny, Frederic4 aut |
700 | 1 | a Medina, Felix4 aut |
700 | 1 | a Babilonia, Noe4 aut |
700 | 1 | a Opolski, Grzegorz4 aut |
700 | 1 | a Vinereanu, Dragos4 aut |
700 | 1 | a Zateyshchikov, Dmitry4 aut |
700 | 1 | a Ruda, Mikhail4 aut |
700 | 1 | a Elamin, Omer4 aut |
700 | 1 | a Kovar, Frantisek4 aut |
700 | 1 | a Dalby, Anthony John4 aut |
700 | 1 | a Jeong, Myung Ho4 aut |
700 | 1 | a Bueno, Hector4 aut |
700 | 1 | a James, Stefan4 aut |
700 | 1 | a Chiang, Chern-En4 aut |
700 | 1 | a Tresukosol, Damras4 aut |
700 | 1 | a Ongen, Zeki4 aut |
700 | 1 | a Ray, Kausik4 aut |
700 | 1 | a Parkhomenko, Alexander4 aut |
700 | 1 | a McGuire, Darren4 aut |
700 | 1 | a Kosiborod, Mikhail4 aut |
700 | 1 | a Nguyen, Tuan Quang4 aut |
700 | 1 | a Wallentin, Lars4 aut |
700 | 1 | a Fox, Keith A. A.4 aut |
700 | 1 | a Eikelboom, John W.4 aut |
700 | 1 | a Tuomilehto, Jaakko4 aut |
700 | 1 | a Lee, Kerry L.4 aut |
700 | 1 | a Al-Khalidi, Hussein R.4 aut |
700 | 1 | a Ellis, Stephen J.4 aut |
700 | 1 | a Hagström, Emilu Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)4 aut0 (Swepub:uu)emhag677 |
700 | 1 | a Holmgren, Pernillau Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)4 aut0 (Swepub:uu)perde159 |
700 | 1 | a Heldestad, Ulrikau Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)4 aut |
700 | 1 | a Hallberg, Theresau Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)4 aut0 (Swepub:uu)theha265 |
700 | 1 | a Renlund Grausne, Karinu Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)4 aut0 (Swepub:uu)kargr743 |
700 | 1 | a Alm, Cristinau Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)4 aut0 (Swepub:uu)crial718 |
700 | 1 | a Michelgård Palmquist, Åsa,d 1973-u Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)4 aut0 (Swepub:uu)asmic254 |
700 | 1 | a Svanberg, Camillau Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)4 aut0 (Swepub:uu)camsv695 |
700 | 1 | a Capell, Warren H.4 aut |
700 | 1 | a Nehler, Mark R.4 aut |
700 | 1 | a Hiatt, William R.4 aut |
700 | 1 | a Bonaca, Marc P.4 aut |
700 | 1 | a Houser, Stacey4 aut |
700 | 1 | a Bachler, Susie4 aut |
700 | 1 | a Jaeger, Nicole4 aut |
700 | 1 | a Aunes, Maria4 aut |
700 | 1 | a Brusehed, Asa4 aut |
700 | 1 | a Chen, Jersey4 aut |
700 | 1 | a Dahlof, Bjorn4 aut |
700 | 1 | a Dolezalova, Jitka4 aut |
700 | 1 | a Domzol, Maciej4 aut |
700 | 1 | a Findley, Magdalena4 aut |
700 | 1 | a Holmberg, Niclas4 aut |
700 | 1 | a Jahreskog, Marianne4 aut |
700 | 1 | a Knutsson, Mikael4 aut |
700 | 1 | a Kruszewski, Jakub4 aut |
700 | 1 | a Leonsson-Zachrisson, Maria4 aut |
700 | 1 | a Stark, Maj4 aut |
700 | 1 | a Winder, Elin4 aut |
710 | 2 | a Harvard Med Sch, Brigham & Womens Hosp, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USAb Imperial Coll, Natl Heart & Lung Inst, London, England;Royal Brompton Hosp, London, England4 org |
773 | 0 | t Clinical Cardiologyd : Wileyg 42:5, s. 498-505q 42:5<498-505x 0160-9289x 1932-8737 |
856 | 4 | u https://doi.org/10.1002/clc.23164y Fulltext |
856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:1329025/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 | u https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/clc.23164 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-387294 |
856 | 4 8 | u https://doi.org/10.1002/clc.23164 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy